Compound #41 Targets Acute Myelogenous Leukemia by Inhibiting the Wnt/β-catenin Signaling Pathway

Yuki Hadate(Kyoto Pharmaceutical University), Eishi Ashihara(Kyoto Pharmaceutical University)
Anticancer Research
October 29, 2024
Cited by 2


Related Papers